Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES study

Critical Care Medicine

Volumn 29, Issue 4, 2001, Pages 765-769

  Reinhart, Konrad ^a   Menges, Thilo ^b   Gardlund, Bengt ^c   Zwaveling, JanHarm ^d   Smithes, Mark ^e   Vincent, Jean Louis ^f   Tellado, Jose Maria ^g   Salgado Remigio, Antonio ^h   Zimlichman, Reuven ⁱ   Withington, Stuart ^j   Tschaikowsky, Klaus ^k   Brase, Rainer ^l   Damas, Pierre ^m   Kupper, Hartmut ⁿ   Kempeni, Joachim ⁿ   Eiselstein, Juergen ⁿ   Kaul, Martin ⁿ  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f ERASME HOSPITAL   (Belgium)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ WOLFSON MEDICAL CENTER   (Israel)

^j ROYAL LONDON HOSPITAL   (United Kingdom)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^l Hospital Links der Weser   (Germany)

^m UNIVERSITY OF LIÈGE   (Belgium)

ⁿ Knoll AG   (Germany)

more..

Author keywords

Clinical trial; Critical illness; Cytokines; Infection; Interleukin 6; Monoclonal antibody; Sepsi; Septic shock; Tumor necrosis factor

Indexed keywords

AFELIMOMAB; CYTOKINE; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HOST RESISTANCE; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEPSIS; TISSUE INJURY;

EID: 0035046049     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200104000-00015     Document Type: Article

References (23)

1. Anti-endotoxin monoclonal antibodies: A second look
2. Management of septic shock: Present and future
3. Has the mortality of septic shock changed with time?
4. Shock and tissue injury induced by human recombinant cachectin
5. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock
6. Factors affecting the measurement of cytokines in biological fluids: Implications for their clinical measurement
7. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
8. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF
9. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
10. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity
11. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
12. Monoclonal antibodies to human tumor necrosis factor alpha: In vitro and in vivo application
13. Tumor necrosis factor-neutralization with a specific monoclonal antibody
14. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
15. Repeated administration of a F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: Effects on the cardiovascular system and cytokine levels
16. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome
17. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
18. A multiple testing procedure for clinical trials
19. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial
20. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial
21. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
22. INTERSEPT an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
23. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein